INmune Bio
INMB
43 hedge funds and large institutions have $25.3M invested in INmune Bio in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 6 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
35% more call options, than puts
Call options by funds: $574K | Put options by funds: $425K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 41 → 43 (+2)
3.05% more ownership
Funds ownership: 10.9% → 13.94% (+3%)
33% less capital invested
Capital invested by funds: $37.7M → $25.3M (-$12.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.24M |
| 2 |
BlackRock
New York
|
+$1.29M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$920K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$424K |
| 5 |
Millennium Management
New York
|
+$402K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.22M |
| 2 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$659K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$517K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$388K |
| 5 |
DCM
DG Capital Management
New York
|
-$388K |
INMB Hedge Fund Activity: Q4 2021 in Review
43 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2021, worth a combined $25.3M — down 33% from $37.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new INMB positions and 6 closed out — a net gain of 2 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.24M. The largest seller was Royal Bank of Canada, cutting an estimated $1.22M.
- 43 institutional investors held INmune Bio (INMB) as of Q4 2021, up from 41 in Q3 2021.
- Funds reported $25.3M of INmune Bio stock for Q4 2021, down 33% quarter-over-quarter.
- 8 funds opened new INmune Bio positions in Q4 2021 and 6 closed out, a net change of +2 holders.
- The largest INmune Bio buyer in Q4 2021 was Morgan Stanley, an estimated $5.24M added.
- The largest INmune Bio seller in Q4 2021 was Royal Bank of Canada, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2021.